ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
68,081.17
-1.48%
S&P 500
5,314.76
0.15%
Dow Jones
39,359.17
-0.79%
US Dollar vs Yen
157.0285
0.20%
Brent Oil
81.375
-0.19%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Cue Biopharma Inc (CUE)

  7. Cue Biopharma Inc (CUE) ニュース

CUE

Cue Biopharma (CUE)

Cue Biopharma Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CUE
日付受信時刻ニュースソース見出しコード企業名
2024/05/1005 : 05GlobeNewswire Inc.Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
2024/05/1005 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CUECue Biopharma Inc
2024/05/1005 : 00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CUECue Biopharma Inc
2024/05/0821 : 00GlobeNewswire Inc.Cue Biopharma to Present at the 20th Annual PEGS Boston SummitNASDAQ:CUECue Biopharma Inc
2024/05/0721 : 00GlobeNewswire Inc.Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceNASDAQ:CUECue Biopharma Inc
2024/04/2423 : 01GlobeNewswire Inc.Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CUECue Biopharma Inc
2024/04/0905 : 05GlobeNewswire Inc.Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsNASDAQ:CUECue Biopharma Inc
2024/04/0221 : 00GlobeNewswire Inc.Cue Biopharma to Host Business Update Call and WebcastNASDAQ:CUECue Biopharma Inc
2024/03/0906 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/03/0906 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/03/0906 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/03/0906 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/03/0100 : 00GlobeNewswire Inc.Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumNASDAQ:CUECue Biopharma Inc
2024/02/2306 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/02/0622 : 00GlobeNewswire Inc.Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:CUECue Biopharma Inc
2024/01/0506 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/01/0506 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2024/01/0506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2023/11/2222 : 00GlobeNewswire Inc.Cue Biopharma to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:CUECue Biopharma Inc
2023/11/1006 : 05GlobeNewswire Inc.Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
2023/11/0722 : 00GlobeNewswire Inc.Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in NovemberNASDAQ:CUECue Biopharma Inc
2023/11/0405 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CUECue Biopharma Inc
2023/11/0401 : 00GlobeNewswire Inc.Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023NASDAQ:CUECue Biopharma Inc
2023/11/0221 : 00GlobeNewswire Inc.Cue Biopharma to Host Business Update Call and WebcastNASDAQ:CUECue Biopharma Inc
2023/09/2722 : 05GlobeNewswire Inc.Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:CUECue Biopharma Inc
2023/09/2621 : 00GlobeNewswire Inc.Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®NASDAQ:CUECue Biopharma Inc
2023/09/1505 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CUECue Biopharma Inc
2023/08/3005 : 08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CUECue Biopharma Inc
2023/08/1005 : 10GlobeNewswire Inc.Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsNASDAQ:CUECue Biopharma Inc
2023/08/0905 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CUECue Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:CUE

最近閲覧した銘柄

BIT
UC4CUM
Unicredit Bank
FX
ARSCHF
ARS vs CHF
ASX
CXX
Cradle Resources
NASDAQ
FMAESX
Senior Loan Select Close...
LSE
SE37
Anz Nz 32 S
NASDAQ
BRLT
Brilliant Earth
USOTC
SGDH
SGD (PK)
NASDAQ
TWCTU
TWC Tech Holdings II
BIT
F18387
Vontobel Financial Produ...
NYSE
BGSF
BGSF
BIT
UC8XW7
Unicredit Bank
NYSE
CRBG
Corebridge Financial
CRTO
KLAYUSDT
Klaytn
NYSE
SBW
ASX
BTUNA
POLO
ETHBTC
Ethereum
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有